Lotrafiban
Title: Lotrafiban
CAS Registry Number: 171049-14-2
CAS Name: (2S)-7-([4,4¢-Bipiperidin]-1-ylcarbonyl)-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid
Manufacturers' Codes: SB-214857
Molecular Formula: C23H32N4O4
Molecular Weight: 428.52
Percent Composition: C 64.47%, H 7.53%, N 13.07%, O 14.93%
Literature References: Specific nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist. Prepn: W. E. Bondinell et al., WO 9518619; W. E. Bondinell, J. M. Samanen, US 6117866 (1995, 2000 both to SmithKline Beecham). Enantiospecific synthesis: W. H. Miller et al., Tetrahedron Lett. 36, 9433 (1995). Structure-activity study: J. M. Samanen et al., J. Med. Chem. 39, 4867 (1996). Binding study: A. Wong et al., J. Pharmacol. Exp. Ther. 285, 228 (1998). Clinical evaluation in patients with coronary or cerebral atherosclerosis: R. A. Harrington et al., Circulation 102 728 (2000). Clinical trial in cerebrovascular and coronary artery disease: E. J. Topol et al., Circulation 108, 399 (2003).
Properties: Zwitterionic. [a]D -200.1° (c = 0.5 in methanol).
Optical Rotation: [a]D -200.1° (c = 0.5 in methanol)
Therap-Cat: Antithrombotic.
Keywords: Fibrinogen Receptor Antagonist; Antithrombotic.
 
 
Status: This monograph has been retired and is no longer subject to revision or update.

Others monographs:
CarbenoxoloneGlycolic Acidγ-Aminobutyric AcidMolindone
Kresoxim-methylAjugarinsNafiverine2-Phenyl-6-chlorophenol
CalusteroneCroceic AcidHydramitrazineFidarestat
Stem Cell FactorCesium ChlorideEtiocobalaminRifampin
©2016 DrugLead US FDA&EMEA